IP Library Granted Patent US 7,943,616
Granted Patent B2
US 7,943,616 · App. 10/995,103 · Granted May 17, 2011

Azaindoles for inhibiting aurora2 and other kinases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,616
App. No.
10/995,103
Granted
May 17, 2011
Kind
B2
Abstract

The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Claims (18)

1. A compound of general formula (I):—

wherein:—

R 1 represents pyrrol-2-yl or indoly-2yl optionally substituted by —C(═O)—R;

R 2 represents hydrogen;

R 3 represents hydrogen, halo, or lower alkyl;

R 4 represents —Z 3 R 7 ;

R 5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R 6 represents hydrogen or lower alkyl;

R 7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R 8 represents hydrogen or lower alkyl;

R represents aryl or heteroaryl; alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, —CHO, —C(═OC)—NY 1 Y 2 , —C(═O)—OR 5 , —NY 1 Y 2 , —N(R 6 )—C(═O)—R 7 , —N(R 6 )—C(═O)—NY 3 Y 4 , —N(R 6 )—SO 2 —R 7 , —N(R 6 )—SO 2 —NY 3 Y 4 , —Z 3 R 7 and one or more groups selected from hydroxy, alkoxy and carboxy;

X 1 represents N;

Y 1 and Y 2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, —C(═O)—NY 3 Y 4 , —C(═O)—OR 5 , —NY 3 Y 4 , —N(R 6 )—C(═O)—R 7 , —N(R 6 )—C(═O)—NY 3 Y 4 , —N(R 6 )—SO 2 —R 7 , —N(R 6 )—SO 2 —NY 3 Y 4 and —OR 7 ; or the group —NY 1 Y 2 may form a cyclic amine;

Y 3 and Y 4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group —NY 3 Y 4 may form a cyclic amine;

Z 2 represents O or S(O) n ;

Z 3 represents O, S(O) n , NR 6 ;

n is zero or an integer 1 or 2;

or an N-oxide, pharmaceutically acceptable salt of such compound; or an N-oxide, of such salt; together with one or more pharmaceutically acceptable carriers or excipients.

Assignments (5)
SECURITY AGREEMENT Recorded Apr 8, 2011
From: AVENTIS PHARMA S.A.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 026100/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2011
From: EDLIN, CHRISTOPHER D.; LAI, JUSTINE YEUN QUAI; MORLEY, ANDREW D.
To: AVENTIS PHARMA LIMITED
Reel/Frame 026091/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2011
From: EDWARDS, MICHAEL L.; COX, PAUL J.; AMENDOLA, SHELLEY; GILLESPY, TIMOTHY A.; GARDNER, CHARLES J.; PEDGRIFT, BRIAN; MAJID, TAHIR N.; KOMINOS, DOROTHEA
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 026091/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2011
From: AVENTIS PHARMA LIMITED
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 026091/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2011
From: DEPRETS, STEPHANIE DANIELE; BOUCHARD, HERVE; HALLEY, FRANK; CLERC, FRANCOIS F.; NEMECEK, CONCEPTION; HOUILLE, OLIVIER; DAMOUR, DOMINIQUE; BEZARD, DANIEL N. A.; CARREZ, CHANTAL
To: AVENTIS PHARMA S.A.
Reel/Frame 026100/0667 →